Table 2.
Ongoing non-CD19 or dual targeted CAR-T Trials for NHL in the US
| NCT | Phase | Target | Disease | Location |
|---|---|---|---|---|
| NCT03081910 | 1 | CD5 | R/R lymphoma or leukemia | BCM |
| NCT03105336 | 2 | CD19 | R/R Indolent B-NHL | Multi-center |
| NCT03019055 | 1 | CD19/20 | R/R B-NHL | MCW |
| NCT03233854 | 1 | CD19/22 | R/R B-NHL or ALL | Stanford |
| NCT03448393 | 1 | CD19/22 | R/R B-NHL or ALL | NCI |
| NCT03330691 | 1/2 | CD19/22 | R/R lymphoma | SCH |
| NCT02153580 | 1 | CD19/EGFR | R/R B-NHL | COH |
| NCT03277729 | 1/2 | CD20 | R/R B-NHL | FHCRC |
| NCT03244306 | 1 | CD22/EGFR | R/R lymphoma or leukemia | SCH |
| NCT03049449 | 1 | CD30 | R/R lymphoma | NCI |
| NCT02917083 | 1 | CD30 | R/R lymphoma | BCM |
| NCT02663297 | 1 | CD30 | Lymphoma s/p autoSCT | UNC |
| NCT02690545 | 1/2 | CD30 | R/R lymphoma | UNC |
| NCT03602157 | 1 | CD30/CCR4 | R/R lymphoma | UNC |
ALL: acute lymphoblastic leukemia; BCM: Baylor College of Medicine; B-NHL: B-cell non-Hodgkin lymphoma; COH: City of Hope; FHCRC: Fred Hutchinson Cancer Research Center; MCW: Medical College of Wisconsin; NCI: National Cancer Institute; SCH: Seattle Children’s Hospital; UNC: University of North Carolina.